Novavax - Vergessene Aktie feiert ein Comeback. Gute Chancen dank aktueller Nachrichtenlage - Älteste Beiträge zuerst (Seite 114)
eröffnet am 25.04.09 09:22:26 von
neuester Beitrag 09.05.24 00:56:15 von
neuester Beitrag 09.05.24 00:56:15 von
Beiträge: 22.863
ID: 1.149.910
ID: 1.149.910
Aufrufe heute: 84
Gesamt: 1.234.357
Gesamt: 1.234.357
Aktive User: 0
ISIN: US6700024010 · WKN: A2PKMZ · Symbol: NVV1
4,1890
EUR
+0,58 %
+0,0240 EUR
Letzter Kurs 13:54:24 Tradegate
Neuigkeiten
01.05.24 · Felix Haupt Anzeige |
16.04.24 · Sharedeals |
18.03.24 · wallstreetONLINE Redaktion |
Werte aus der Branche Biotechnologie
Wertpapier | Kurs | Perf. % |
---|---|---|
2,4000 | +49,07 | |
2,1000 | +33,76 | |
4,0600 | +27,67 | |
1,6400 | +25,19 | |
26,45 | +23,02 |
Wertpapier | Kurs | Perf. % |
---|---|---|
2,9800 | -22,84 | |
0,6700 | -26,58 | |
0,6864 | -32,57 | |
2,1300 | -34,41 | |
3,1600 | -38,64 |
Ich bin mal wieder mit einer ersten Position hier rein. Der Anstieg gestern sah schon gut aus, schönes Volumen und fast auf Tageshoch geschlossen.
könnte was werden. Bin auch am überlegen. Der Rebound könnte aber auch noch etwas dauern, so er denn kommt
...bin heute morgen auch mal auf Verdacht rein...
Novavax: 'We still expect to enjoy the advantage of being the first RSV vaccine'
Feb 28, 2017, 7:10am EST Updated Feb 28, 2017, 10:10am EST
Gaithersburg-based Novavax executives still believe their company is leading the race to produce a vaccine against respiratory syncytial virus, or RSV, they told investors during a Monday earnings call.
Novavax (NASDAQ: NVAX) recently opened a phase 2 clinical trial to begin retesting its previous lead vaccine candidate for elderly patients after suffering a devastating failed phase 3 clinical trial in September. RSV is the most common cause of pneumonia and inflammation of the small airways in lungs in children under 1. It impacts other age groups as well.
They expect results back by the third quarter.
At the same time, Novavax has redirected its focus into a phase 3 clinical trial for an RSV vaccine for infants via maternal immunization. The company is in discussions with the U.S. Food and Drug Administration over whether it can begin an informational analysis of that vaccine candidate's efficacy, officials said. That would enable to company to begin preparing for commercialization.
“We continue to believe there is a multi-billion opportunity for our RSV-F franchise and we still expect to enjoy the advantage of being the first RSV vaccine to market,” Novavax President and CEO Stanley Erck said.
Other companies working on RSV vaccines include Gaithersburg-based MedImmune, which is the research and development arm for AstraZeneca, and GlaxoSmithKline.
Novavax reported a net loss $57.1 million during the fourth quarter, surpassing some analysts expectations. It was an improvement over the same quarter in 2015, when it reported a net loss of $78.8 million.
The company reported a loss of $280 million for 2016, compared to a net loss of $156.9 million in 2015. Revenue was less than half it was in 2015 — $15.4 million compared to $36.3 million. Officials blamed the decrease in revenue on the expiration of a federal contract and said the funding was partially offset by funding from the Bill and Melinda Gates Foundation. Novavax is supported by an $89 million grant from the Gates Foundation for its efforts to create an RSV vaccine for infants.
Novavax is also working to create a vaccine candidate for Zika with a goal of beginning a Phase 1 trial later this year. On Monday, Erck told analysts he believes the U.S. will continue to prioritize Zika because of its devastating effects on pregnancies.
http://www.bizjournals.com/washington/news/2017/02/28/novava…
Ich hatte nach den Zahlen eigentlich Kurse unter 1,40$ erwartet, aber ist ja gut so.
Feb 28, 2017, 7:10am EST Updated Feb 28, 2017, 10:10am EST
Gaithersburg-based Novavax executives still believe their company is leading the race to produce a vaccine against respiratory syncytial virus, or RSV, they told investors during a Monday earnings call.
Novavax (NASDAQ: NVAX) recently opened a phase 2 clinical trial to begin retesting its previous lead vaccine candidate for elderly patients after suffering a devastating failed phase 3 clinical trial in September. RSV is the most common cause of pneumonia and inflammation of the small airways in lungs in children under 1. It impacts other age groups as well.
They expect results back by the third quarter.
At the same time, Novavax has redirected its focus into a phase 3 clinical trial for an RSV vaccine for infants via maternal immunization. The company is in discussions with the U.S. Food and Drug Administration over whether it can begin an informational analysis of that vaccine candidate's efficacy, officials said. That would enable to company to begin preparing for commercialization.
“We continue to believe there is a multi-billion opportunity for our RSV-F franchise and we still expect to enjoy the advantage of being the first RSV vaccine to market,” Novavax President and CEO Stanley Erck said.
Other companies working on RSV vaccines include Gaithersburg-based MedImmune, which is the research and development arm for AstraZeneca, and GlaxoSmithKline.
Novavax reported a net loss $57.1 million during the fourth quarter, surpassing some analysts expectations. It was an improvement over the same quarter in 2015, when it reported a net loss of $78.8 million.
The company reported a loss of $280 million for 2016, compared to a net loss of $156.9 million in 2015. Revenue was less than half it was in 2015 — $15.4 million compared to $36.3 million. Officials blamed the decrease in revenue on the expiration of a federal contract and said the funding was partially offset by funding from the Bill and Melinda Gates Foundation. Novavax is supported by an $89 million grant from the Gates Foundation for its efforts to create an RSV vaccine for infants.
Novavax is also working to create a vaccine candidate for Zika with a goal of beginning a Phase 1 trial later this year. On Monday, Erck told analysts he believes the U.S. will continue to prioritize Zika because of its devastating effects on pregnancies.
http://www.bizjournals.com/washington/news/2017/02/28/novava…
Ich hatte nach den Zahlen eigentlich Kurse unter 1,40$ erwartet, aber ist ja gut so.
Das Warten Spiel zerschlagen Novavax, Inc. im März, Versand von Aktien nach unten 15%
Die Bargeldrate des Unternehmens ist ein ernstes Anliegen.
https://www.fool.com/investing/2017/04/05/the-waiting-game-c…
LG tz
Die Bargeldrate des Unternehmens ist ein ernstes Anliegen.
https://www.fool.com/investing/2017/04/05/the-waiting-game-c…
LG tz
So Leute bin rein zu 0,86$ viel billiger geht's nicht mehr außer es geht alles total den Bach runter
LG Printi
LG Printi
Antwort auf Beitrag Nr.: 54.690.257 von printguru am 06.04.17 15:49:31
Doch, 0,77$ !!!
LG tz
Zitat von printguru: So Leute bin rein zu 0,86$ viel billiger geht's nicht mehr außer es geht alles total den Bach runter
LG Printi
Doch, 0,77$ !!!
LG tz
Breaking Down: Novavax Inc (NASDAQ: NVAX) Stock Drop Unten Support - Techniken Hit Extreme Schwäche.
http://news.cmlviz.com/2017/04/06/breaking-down-novavax-inc-…
LG tz
http://news.cmlviz.com/2017/04/06/breaking-down-novavax-inc-…
LG tz
Es ist ja so: Die Kassen bei Novavax sind leer. Sie werden um eine KE nicht ...........................wie sagt man.
Eine KE wird sich nicht vermeiden lassen. Das sind meine Einschätzungen zum jetzigen Zeitpunkt.
Vielleicht spielt der heutige Kursverfall da schon eine gewisse Rolle ?
Wir werden in den nächsten Wochen sicherlich etwas lesen.
LG tz
Eine KE wird sich nicht vermeiden lassen. Das sind meine Einschätzungen zum jetzigen Zeitpunkt.
Vielleicht spielt der heutige Kursverfall da schon eine gewisse Rolle ?
Wir werden in den nächsten Wochen sicherlich etwas lesen.
LG tz
Hallo
Man muss kein Prophet sein, um zu wissen das jetzt ein Betrügerischer Revers Split kommen wird, dass haben die pharmaceutigal companies leider in sich.
Beste Grüsse
Man muss kein Prophet sein, um zu wissen das jetzt ein Betrügerischer Revers Split kommen wird, dass haben die pharmaceutigal companies leider in sich.
Beste Grüsse
Beitrag zu dieser Diskussion schreiben
Investoren beobachten auch:
Wertpapier | Perf. % |
---|---|
+0,03 | |
-0,36 | |
-1,16 | |
+0,59 | |
-2,77 | |
-1,07 | |
+0,83 | |
+1,20 | |
+0,12 | |
0,00 |
Meistdiskutiert
Wertpapier | Beiträge | |
---|---|---|
168 | ||
90 | ||
89 | ||
89 | ||
76 | ||
65 | ||
49 | ||
38 | ||
33 | ||
28 |
16.04.24 · Sharedeals · Novavax |
18.03.24 · wallstreetONLINE Redaktion · Guess? |
03.03.24 · wO Chartvergleich · Allianz |
29.02.24 · Sharedeals · Novavax |
28.02.24 · BörsenNEWS.de · Novavax |
28.02.24 · wallstreetONLINE Redaktion · Novavax |
25.02.24 · wO Chartvergleich · ENCAVIS |
23.02.24 · PR Newswire (dt.) · Novavax |
22.02.24 · wallstreetONLINE Redaktion · Novavax |
21.02.24 · wO Chartvergleich · Dow Jones |